Sign inJoin waitlistJoin the waitlist

Mitchell Cairo

Fellowship Program Director · Westchester Medical Center

Credentials: · · ·

History

Westchester Medical Center Fellowship
Present
Oncology and Stem Cell Transplantation Division · Westchester Medical Center
Present
Pediatrics · New York Medical College
Present

University of California-San Francisco
1981–1982
Pediatric Hematology Oncology
Indiana University School of Medicine
1978–1981
Harbor-UCLA Medical Center
1976–1978
University of California, San Francisco (USCF
Univ of California, San Francisco Sch of Med
1972–1976
University of Wisconsin (UW
1968–1972

Research

Tumour lysis syndrome: new therapeutic strategies and classification
Review · British Journal of Haematology · 2004 · First of 2 authors · Corresponding · 728 citations
Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors
New England Journal of Medicine · 2001 · 666 citations
Risk factors for acute GVHD and survival after hematopoietic cell transplantation
Blood · 2012 · 567 citations

Sherrie Perkins
53 papers
Hillard Lazarus
45 papers
Prakash Satwani
41 papers · 14 as a fellow
Daniel Weisdorf
35 papers
BS
Bipin Savani
29 papers
James Garvin
28 papers
Mark Litzow
26 papers
Monica Bhatia
25 papers
Jessica Hochberg
24 papers · 6 as a fellow
Diane George
23 papers
GH
Gregory Hale
23 papers
RK
Rammurti Kamble
23 papers

Grants

A Randomized Study of Maternal Donor Derived CMV Cytotoxic T-Lymphocytes (CTLs) and Valganciclovir vs Valganciclovir in Neonates With Moderate/Severe Maternal Acquired CMV Infection
Food and Drug Administration · R01
Contact PI · $1.3M · New York Medical College
2023–2028
Novel Immunomodulation and Facilitation of “Suppression Proof” CAR NK Cell Against Ewing Sarcoma
National Cancer Institute · U54
PI · $498.7K · Research Inst Nationwide Children's Hosp
2022–2025
CMV, ADV and EBV Viral Cytotoxic T-Lymphocytes Generated by a Novel Cytokine Capture System in Children,Adolescents and Young Adults with Refractory Viral Infection and T-Cell Immunodeficiency
Food and Drug Administration · R01
Contact PI · $1.7M · New York Medical College
2019–2024
Seventh International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma
National Cancer Institute · R13
Contact PI · $4.5K · New York Medical College
2022–2023

Clinical trials

CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
Principal investigator · Not yet recruiting · Phase 1, Phase 2
New York Medical College
2026–2040
CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma
Principal investigator · Not yet recruiting · Phase 1
New York Medical College
2026–2032
Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone
Principal investigator · Recruiting · Phase 3
New York Medical College
2026–2032
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
Principal investigator · Recruiting · Phase 2
New York Medical College
2025–2030